On Thursday, shares in the UK headquartered Bristol-Myers Squibb Co. recorded a trading volume of 6.82 million shares. The stock ended the day 0.85% higher at $56.68. Shares of the Company are trading at a PE ratio of 28.23. Bristol-Myers Squibb's stock has gained 13.66% in the last one month. The stock is trading above its 50-day moving average by 6.51%. Furthermore, shares of Bristol-Myers Squibb have a Relative Strength Index (RSI) of 67.00.
On October 28th, 2016, research firm Deutsche Bank reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $59 a share to $52 a share.
On November 16th, 2016, Bristol-Myers Squibb and Enterome S.A. announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb's Immuno-Oncology portfolio. Free research report on BMY is available at:
AstraZeneca PLC's stock finished Thursday's session 0.18% lower at $27.35 with a total volume of 7.91 million shares traded. Shares of the Company are trading below its 50-day and 200-day moving averages by 11.78% and 8.93%, respectively. AstraZeneca's stock traded at a PE ratio of 31.15 and has an RSI of 30.52.
On November 11th, 2016, results from the international, multicenter ChildHood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms significantly improved lung function in paediatric patients between 6 to <12 years of age with asthma versus budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population. AstraZeneca conducted the CHASE 3 study after the US FDA requested additional data on budesonide and formoterol, specifically regarding the impact of different doses, in paediatric asthma patients between 6 to <12 years of age. The complimentary research report on AZN can be downloaded at:
Florida headquartered TherapeuticsMD Inc.'s stock advanced 2.67%, to close the day at $6.91. The stock recorded a trading volume of 1.77 million shares, which was above its three months average volume of 1.74 million shares. TherapeuticsMD's shares have gained 15.36% in the last one month and 0.14% in the previous three months. Shares of the Company are trading 9.29% above its 50-day moving average. Additionally, the stock has an RSI of 64.89.
On November 3rd, 2016, TherapeuticsMD announced two new strategic hires: Dawn Halkuff, as Chief Commercial Officer, and Yulii Bogatyrenko, as Senior Vice President of Business Development. Both executives bring women's health experience and relevant skills to the company in advance of the potential launch of its first bio-identical hormone therapy drug candidate in the second half of 2017. Dawn Halkuff was previously at Pfizer, where she held various leadership roles in women's health since 2010. Yulii Bogatyrenko was most recently the Senior Vice President of Business Development at Paratek Pharmaceuticals, Inc.
On November 7th, 2016, research firm Guggenheim resumed its 'Buy' rating on the Company's stock. Visit us today and access our complete research report on TXMD at:
On Thursday, shares in New York-based Tonix Pharmaceuticals Holding Corp. ended the session 3.70% lower at $0.41 with a total volume of 329,671 shares traded. The stock is trading 33.52% below its 50-day moving average and 79.41% below its 200-day moving average. Moreover, shares of the Company have an RSI of 28.86.
On November 10th, 2016, Tonix reported a net loss of $7.6 million, or $0.29 per share, for Q3 2016 compared to a net loss of $13.3 million, or $0.72 per share, for Q3 2015. Cash used in operations was $8.4 million for Q3 2016 compared to $12.3 million for Q3 2015. At September 30th, 2016, Tonix's cash, cash equivalents, and marketable securities totaled $26.7 million compared to $43.0 million at December 31st, 2015. Management believes that Tonix's existing funds are sufficient to fund its operating expenses and clinical activity for at least the next 12 months. Get free access to your research report on TNXP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA